Establishment and validation of the scoring system for preoperative prediction of central lymph node metastasis in papillary thyroid carcinoma

Wen Liu1, Ruochuan Cheng1, Yunhai Ma3, Dan Wang3, Yanjun Su1, Chang Diao3, Jianming Zhang3, Jun Qian1 & Jin Liu1

Early preoperative diagnosis of central lymph node metastasis (CNM) is crucial to improve survival rates among patients with papillary thyroid carcinoma (PTC). Here, we analyzed clinical data from 2862 PTC patients and developed a scoring system using multivariable logistic regression and testified by the validation group. The predictive diagnostic effectiveness of the scoring system was evaluated based on consistency, discrimination ability, and accuracy. The scoring system considered seven variables: gender, age, tumor size, microcalcification, resistance index >0.7, multiple nodular lesions, and extrathyroid extension. The area under the receiver operating characteristic curve (AUC) was 0.742, indicating a good discrimination. Using 5 points as a diagnostic threshold, the validation results for validation group had an AUC of 0.758, indicating good discrimination and consistency in the scoring system. The sensitivity of this predictive model for preoperative diagnosis of CNM was 4 times higher than a direct ultrasound diagnosis. These data indicate that the CNM prediction model would improve preoperative diagnostic sensitivity for CNM in patients with papillary thyroid carcinoma.

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer1–5. Patients with thyroid nodules often require ultrasound (US) examination6–8, which has become the preferred diagnostic method for PTC because of its convenience, sensitivity, non-invasive and non-radioactive nature, and economical and diagnostic value9. Cervical lymph node metastasis is the most common metastatic pathway of PTC, with a central metastasis rate of 20–50%10–12. However, the sensitivity of US detection of lymph node metastasis is only 20–38%13–15. Especially the assessment of deep lymph nodes in central regions is difficult (e.g., posterior pharynx and mediastinum). If analyzed by physicians with limited experience in US imaging, the accuracy might be further reduced, even after combining with other imaging methods. This may cause a delay in 20% of the surgical programs, missing the best timing of treatment and affecting prognosis10,16. Since diagnosis of PTC metastasis requires highly sensitive diagnostic methods, there is an urgent need to develop reliable prediction methods of PTC metastasis.

Several studies have indicated that clinical characteristics, including age, gender, and multifocal tumor location, might have a predictive value in the central lymph node metastasis (CNM) of PTC17–20. In addition, scans of PTC metastatic lymph nodes often show the same ultrasound and pathological manifestations as the scans of primary lesions, such as microcalcifications and blood flow changes. In this study, we reviewed the ultrasound images of patients with preoperative diagnosis of PTC within the last 10 years, and analyzed the relationship between ultrasonographic features of PTC tumors and CNM. We then developed a novel scoring system that should improve the sensitivity of preoperative CNM diagnosis.

1Department of Thyroid Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China. 2Department of health management center, The First Affiliated Hospital of Kunming Medical University, Kunming, China. Correspondence and requests for materials should be addressed to R.C. (email: cruochuan@foxmail.com)
Results

Basic characteristics of the research subjects. A total of 3801 patients were preoperatively diagnosed with PTC in the Thyroid Center of Kunming Medical University First Affiliated Hospital from January 2007 to June 2016. The diagnosis of PTC was mainly based on US-guided fine-needle aspiration biopsy. Postoperative pathology confirmed that 3553 cases had PTC and 248 cases were misdiagnosed due to other benign diseases, with a PPV of 93.5%. Therefore, a total of 2862 cases were included in the study, among which 1240 cases were CNM positive and 1622 cases were negative with a metastasis rate of 43.2% using postoperative paraffin pathology. However, only 265 cases (sensitivity of 16.8%) were diagnosed with CNM or suspicious metastasis by preoperative US diagnosis. Moreover, 1918 cases (~67%) were in the modeling group, had a median age of 42 years (ranged 9–88), and included 384 males (20.0%) and 1534 females (80.0%); 856 cases (44.6%) were CNM positive. The CND median was 8 (5, 12) nodes, and the mean metastases number was 1.7 (±3.4). Further, 944 cases were in the validation group (about 33%), had a median age of 43 years (ranging 10–79), and included 165 males (17.5%) and 779 females (82.5%); 384 cases (40.7%) were CNM positive. The CND median was 8 (5, 12) nodes, and the mean metastases number was 1.5 (±2.7). No significant difference was found in demographic profiles between the two groups.

Establishment and evaluation of prediction model and its scoring system. The study was based on clinical features and ultrasonographic characteristics, excluding features that could cause interference. A total

| Modeling | Total | CNM(−) | CNM(+) | P value | Validation | Total | CNM(−) | CNM(+) | P value |
|----------|-------|--------|--------|---------|------------|-------|--------|--------|---------|
|          | N = 1918 | N = 1062 | N = 856 |         | N = 944 | N = 560 | N = 384 |         |         |
| Gender   |        |        |        | <0.001 |          |        |        |        | <0.001 |
| Male     | 384 (20.0%) | 166 (15.6%) | 218 (25.5%) | 165 (17.2%) | 74 (13.2%) | 91 (23.7%) | |
| Female   | 1534 (80.0%) | 896 (84.4%) | 638 (74.5%) | 779 (82.5%) | 486 (86.8%) | 293 (76.3%) | |
| Age      |        |        |        | <0.001 |          |        |        |        | <0.001 |
| ≤40 years | 838 (43.7%) | 365 (34.4%) | 473 (55.3%) | 375 (39.7%) | 169 (30.2%) | 206 (53.6%) | |
| >40 years | 1080 (56.3%) | 697 (65.6%) | 383 (44.7%) | 569 (60.6%) | 391 (69.8%) | 178 (46.4%) | |
| Tumor size |        |        |        | <0.001 |          |        |        |        | <0.001 |
| ≤1 cm    | 1169 (61.0%) | 793 (74.7%) | 376 (43.9%) | 582 (61.7%) | 419 (74.8%) | 163 (42.4%) | |
| 1–2 cm   | 530 (27.6%) | 211 (19.9%) | 319 (37.3%) | 273 (28.9%) | 118 (21.1%) | 155 (40.4%) | |
| 2–3 cm   | 163 (8.5%) | 51 (4.8%) | 112 (13.1%) | 59 (6.3%) | 19 (3.4%) | 40 (10.4%) | |
| >3 cm    | 56 (2.9%) | 7 (0.6%) | 19 (2.2%) | 30 (3.2%) | 4 (0.7%) | 26 (6.8%) | |
| Microcalcification |        |        |        | <0.001 |          |        |        | <0.001 |
| No       | 733 (38.2%) | 469 (44.2%) | 264 (30.8%) | 345 (36.5%) | 239 (42.7%) | 106 (27.6%) | |
| Scattered distribution | 966 (50.4%) | 491 (46.2%) | 475 (55.5%) | 470 (49.8%) | 254 (45.4%) | 216 (56.3%) | |
| Aggregated distribution | 219 (11.4%) | 102 (9.6%) | 117 (13.7%) | 129 (13.7%) | 67 (12.0%) | 62 (16.1%) | |
| Shape    |        |        |        | 0.899   |          |        |        | 0.124  |
| Normal   | 450 (23.5%) | 248 (23.4%) | 202 (23.6%) | 224 (23.7%) | 123 (22.0%) | 101 (26.3%) | |
| Abnormal | 1468 (76.5%) | 814 (76.6%) | 654 (76.4%) | 720 (76.3%) | 437 (78.0%) | 283 (73.7%) | |
| Internal blood supply |        |        |        | <0.001 |          |        |        | 0.002  |
| Not rich | 1484 (77.4%) | 858 (80.8%) | 626 (73.1%) | 726 (76.9%) | 450 (80.4%) | 276 (71.9%) | |
| Rich     | 434 (22.6%) | 204 (19.2%) | 230 (26.9%) | 218 (23.1%) | 110 (19.6%) | 108 (18.1%) | |
| Internal blood vessels | 0.737   |          |        |        |          |        |        | 0.104  |
| Normal   | 1614 (84.2%) | 891 (83.9%) | 723 (84.5%) | 802 (85.0%) | 467 (83.4%) | 335 (87.2%) | |
| Abnormal | 304 (15.8%) | 171 (16.1%) | 133 (15.5%) | 142 (15.0%) | 93 (16.6%) | 49 (12.8%) | |
| RI > 0.7 |        |        |        | <0.001 |          |        |        | 0.002  |
| No       | 1494 (77.9%) | 878 (82.7%) | 616 (72.0%) | 746 (79.0%) | 462 (82.5%) | 284 (74.0%) | |
| Yes      | 424 (22.1%) | 184 (17.3%) | 240 (28.0%) | 198 (21.0%) | 98 (17.5%) | 100 (26.0%) | |
| Multiple nodular lesions | 0.039   |          |        |        |          |        |        | 0.018  |
| No       | 730 (38.1%) | 426 (40.1%) | 304 (35.5%) | 342 (36.2%) | 220 (39.3%) | 122 (31.8%) | |
| Yes      | 1188 (61.9%) | 636 (59.9%) | 552 (64.5%) | 602 (63.8%) | 340 (60.7%) | 262 (68.2%) | |
| Hashimoto's disease | 0.926   |          |        |        |          |        |        | 0.001  |
| No       | 1284 (66.9%) | 710 (66.9%) | 574 (67.1%) | 858 (90.9%) | 536 (95.7%) | 322 (83.9%) | |
| Yes      | 634 (33.1%) | 352 (33.1%) | 282 (32.9%) | 86 (9.1%) | 24 (4.3%) | 62 (16.1%) | |
| Extraesophageal extension |        |        |        | <0.001 |          |        |        | <0.001 |
| No       | 1743 (90.9%) | 1020 (96.0%) | 723 (84.5%) | 858 (90.9%) | 536 (95.7%) | 322 (83.9%) | |
| Yes      | 175 (9.1%) | 42 (4.0%) | 133 (15.5%) | 86 (9.1%) | 24 (4.3%) | 62 (16.1%) | |

Table 1. Relationship between clinical and US characteristics, and CNM of patients in the modeling and validation groups. CNM, central lymph node metastases; RI, resistance index.
of 11 variables were included. The single-factor analysis showed that CNM was associated with gender, age, tumor size, microcalcifications, internal blood supply, RI > 0.7, multiple nodule lesions, and extrathyroid extensions (\(P < 0.05\), Table 1). The CNM predictive model and scoring system were established based on the logistic regression model for the diagnosis of patients with PTC. They comprised gender, age, tumor size, microcalcifications, RI > 0.7, nodular lesions, and extrathyroid extensions; the \(\beta\) value of multiple nodular lesions was the smallest (Table 2). The \(\beta\) value of other variables was divided by the corresponding minimum regression coefficient. The prediction scores ranged from 0–9. The proportion of CNM in the subjects increased with increasing scores (Table 3). The results of Hosmer–Lemeshow goodness-of-fit test showed that the logistic regression model had a good calibration (\(\chi^2 = 9.065, P = 0.337\)). The area under the curve (AUC) of ROC was 0.742 [95% confidence interval (CI), 0.720–0.764], indicating a good discrimination of logistic regression model (Fig. 1).

The Youden index reached a maximum (0.359) when the score was equal or more than 5 points in the scoring system, and the subjects were divided into a low-risk CNM population group (1067 cases, 55.6%) and a high-risk CNM population group (856 cases, 44.4%) (Table 3). The high-risk group (≥ 5 points) included 64.3% (550/856) of CNM cases, and its CNM rate (64.6%, 550/851) was significantly higher compared with that of the low-risk population group (< 5 points) (28.7%, 307/1067). Under the predicted threshold, the CNM sensitivity, specificity, PPV, NPV, PLR, and NLR were predicated as 64.3%, 71.7%, 64.7%, 71.4%, 2.272, and 0.395, respectively. The detection rates of CNM in the high-risk and low-risk population groups were 64.6% (51.2–100%) and 28.7% (16.2–34.3%), respectively.

The prediction scoring system was then applied to evaluate validation group, showing 43.9% in the high-risk population group (≥ 5 points) and 56.1% in the low-risk population group (< 5 points). The proportion of CNM cases in the two risk stratification groups were 62.3% and 23.8%, respectively, similar to the modeling population. The AUC of ROC was 0.758 (95% CI, 0.727–0.789), which was similar to the discrimination of the modeling population (0.742 in AUC of ROC). The results of Hosmer–Lemeshow goodness-of-fit test showed that the logistic regression model had good consistency (\(\chi^2 = 2.449, P = 0.931\)). Under the predicted threshold, the sensitivity, specificity, PPV, NPV, PLR, and NLR of CNM were predicted as 67.2%, 72.1%, 62.3%, 76.2%, 2.409, and 0.387, respectively, in the scoring system. The detection rates of CNM in the high-risk and low-risk population groups were 62.3% (45.8–100%) and 23.8% (7.3–37.9%), respectively (Fig. 1).

**Discussion**

This study has established a prediction model and its scoring system for preoperative diagnosis of CNM in PTC. The model consists of seven variables: gender, age, tumor size, microcalcifications, RI > 0.7, multiple nodular

| Parameter | \(\beta\) | SE | Wald | \(P\) | OR | Lower | Upper | Points assigned |
|-----------|----------|----|------|------|----|-------|-------|----------------|
| Gender    |          |    |      |      |    |       |       |                |
| Female    |          |    |      |      |    |       |       |                |
| Male      | 0.53     | 0.126 | 17.761 | <0.001 | 1.699 | 1.327 | 2.175 | 2              |
| Age       |          |    |      |      |    |       |       |                |
| >40 years |          |    |      |      |    |       |       |                |
| ≤40 years | 0.763    | 0.103 | 55.07 | <0.001 | 2.103 | 1.753 | 2.624 | 2              |
| Tumor size|          |    |      |      |    |       |       |                |
| ≤1 cm     |          |    |      |      |    |       |       |                |
| 1–2 cm    | 0.963    | 0.115 | 70.291 | <0.001 | 2.620 | 2.092 | 3.281 | 3              |
| 2–3 cm    | 1.213    | 0.19 | 40.75 | <0.001 | 3.364 | 2.318 | 4.882 | 4              |
| >3 cm     | 2.385    | 0.42 | 32.247 | <0.001 | 10.857 | 4.767 | 24.728 | 9              |
| Microcalcification | |    |      |      |    |       |       |                |
| No        |          |    |      |      |    |       |       |                |
| Scattered distribution | 0.395 | 0.11 | 12.91 | <0.001 | 1.484 | 1.197 | 1.841 | 1              |
| Aggregated distribution | 0.532 | 0.171 | 9.738 | 0.002 | 1.703 | 1.219 | 2.378 | 2              |
| RI > 0.7  |          |    |      |      |    |       |       |                |
| No        |          |    |      |      |    |       |       |                |
| Yes       | 0.293    | 0.124 | 5.57 | 0.018 | 1.34 | 1.051 | 1.709 | 1              |
| Multiple nodular lesions | |    |      |      |    |       |       |                |
| No        |          |    |      |      |    |       |       |                |
| Yes       | 0.26     | 0.105 | 6.075 | 0.014 | 1.297 | 1.055 | 1.595 | 1              |
| extrathyroid extension | |    |      |      |    |       |       |                |
| No        |          |    |      |      |    |       |       |                |
| Yes       | 1.263    | 0.198 | 40.534 | <0.001 | 3.535 | 2.397 | 5.215 | 4              |
| Constant  | −1.696   | 0.129 | 173.493 | 0.001 | 0.183 |       |       |                |

**Table 2.** Multivariate logistic regression model and scoring system for CNM prediction. CNM, central lymph node metastases; RI, resistance index.
lesions, and extrathyroid extensions. The detection rates of CNM in the modeling and validation groups of high-risk population are 64.6% and 62.3%, respectively. The predictive model has a high prediction consistency, discrimination ability, and accuracy. The same results were obtained using the scoring system, indicating that the model has an important value for CNM risk stratification in patients with PTC, and can improve the sensitivity of preoperative diagnosis of CNM.

Our results indicate that the sonographic features of the primary foci of PTC are related to CNM. Since other primary foci imaging features also correlate with CNM, they might be used in an early CNM diagnosis. Screening of high risk groups for prophylactic central cleaning, and screening of low risk population may improve the diagnostic sensitivity of central lymph node metastasis.

Ultrasonographic microcalcification occurs in about 34–66% of malignant nodules, mainly associated with the sand formation of papillary carcinoma. Microcalcification was located in the nipple cadre and fibrous interstitial, and could also be located among solid tumor cell nests; it was extremely rare in other thyroid lesions. Similar structures of psammoma bodies might appear in the cervical lymph node metastases. Concentric

Table 3. CNM detection rate of risk score and risk stratification in modeling population and validation population in the established model using preoperative factors. *The number of cases with CNM and its risk score or proportion of risk stratification.

| Risk score | Number  | CNM(+)* | Risk stratification | Total | CNM(+)* |
|------------|---------|---------|---------------------|-------|---------|
| Modeling population | 1918 (100.0%) | 856 (44.6%) | | | |
| 0 | 74 | 12 (16.2%) | Low (0–4) | 1067 (55.6%) | 306 (28.7%) |
| 1 | 244 | 39 (16.0%) | | | |
| 2 | 263 | 68 (25.9%) | | | |
| 3 | 240 | 78 (32.5%) | | | |
| 4 | 246 | 109 (34.3%) | | | |
| 5 | 201 | 103 (51.2%) | High (≥5) | 851 (44.4%) | 550 (64.6%) |
| 6 | 162 | 93 (57.4%) | | | |
| 7 | 155 | 97 (52.6%) | | | |
| 8 | 108 | 75 (69.4%) | | | |
| 9 | 68 | 49 (72.1%) | | | |
| 10 | 38 | 27 (71.1%) | | | |
| 11 | 38 | 35 (92.1%) | | | |
| 12 | 29 | 25 (86.2%) | | | |
| 13 | 21 | 17 (81.0%) | | | |
| 14 | 13 | 11 (84.6%) | | | |
| 15 | 3 | 3 (100.0%) | | | |
| 16 | 10 | 10 (100.0%) | | | |
| 17 | 3 | 3 (100.0%) | | | |
| 18 | 1 | 1 (100.0%) | | | |
| 19 | 1 | 1 (100.0%) | | | |
| Validation population | 944 (100.0%) | 384 (40.7%) | | | |
| 0 | 41 | 3 (7.5%) | Low (0–6) | 530 (56.1%) | 126 (23.8%) |
| 1 | 116 | 16 (13.8%) | | | |
| 2 | 131 | 32 (24.4%) | | | |
| 3 | 118 | 28 (23.7%) | | | |
| 4 | 124 | 47 (37.9%) | | | |
| 5 | 107 | 49 (45.8%) | High (≥5) | 414 (43.9%) | 258 (62.3%) |
| 6 | 96 | 55 (57.3%) | | | |
| 7 | 70 | 48 (68.6%) | | | |
| 8 | 41 | 25 (61.0%) | | | |
| 9 | 26 | 20 (76.9%) | | | |
| 10 | 24 | 18 (75.5%) | | | |
| 11 | 12 | 10 (83.3%) | | | |
| 12 | 12 | 9 (75.5%) | | | |
| 13 | 12 | 11 (91.7%) | | | |
| 14 | 4 | 4 (100.0%) | | | |
| 15 | 5 | 5 (100.0%) | | | |
| 16 | 3 | 3 (100.0%) | | | |
| 17 | 1 | 0 (0.0%) | | | |
| 18 | 1 | 1 (0.0%) | | | |
A roundness-positive body was seen after mucus, calcium, and iron staining, and its center had visible necrotic tumor cells, representing the original place of the formation of psammoma bodies. Our data suggest that psammoma bodies are associated with aggressive behaviors of PTC, and that other features might be used as predictors before the formation of psammoma bodies in lymph node metastases (Figs 2 and 3). A previous study reported that microcalcification could be used as an independent predictor of CNM in papillary microcarcinoma (odds ratio (OR), 2.378; 95% CI, 1.096–5.158). In this study, 62.3% of the cases showed microcalcifications (1784/2862). Among them, 1185 cases were in the modeling group; the statistical analysis was based on the distribution trend of microcalcification. Our results indicate that both scattered and aggregated distribution of microcalcifications can be used as an independent risk factor for CNM (OR, 1.484; 95% CI, 1.197–1.816 vs OR, 1.703; 95% CI, 1.219–2.378).

Figure 1. (A) The ROC curve of the modeling group. (B) The ROC curve of the validation group.

Figure 2. The same left thyroid nodule of a female patient (46 years) was observed for more than 6 years, and changes in the nodule were observed using US images. (A) In August 2008, the nodular size found using US was 0.8 × 0.8 cm², with regular shape and without microcalcification; the diagnosis was benign. (B) In September 2013, the nodular size was 1.2 × 1.1 cm², with irregular shape and edge angulation, and scattered microcalcification inside the nodule; the diagnosis was suspected malignancy. (C,D) In September 2014, the nodular size was 1.3 × 1.1 cm², with irregular shape, scattered microcalcification in both the nodule and the left central lymph node medulla; the diagnosis was left thyroid cancer and CNM.
Several studies have indicated that increased nodular blood flow signals are associated with malignancy\textsuperscript{24,25}. However, using a multivariate logistic regression analysis, Moon et al.\textsuperscript{26} did not identify an increased nodular blood flow as an independent predictor of thyroid cancer. In this study, only internal blood supply of tumors was used as an indicator, and a total of 1716 cases (~60%) were found to have a visible internal blood supply using Doppler energy. In the modeling group, the internal blood supply of nodules was associated with CNM, and the difference was statistically significant (\( P < 0.001 \)). However, it could not be used as an independent predictor of CNM in the multivariable analysis, so it was not included in this scoring system. Malignant cells can release vascular endothelial growth factor that stimulates angiogenesis within tumors. Adamczewski et al.\textsuperscript{27} have suggested that the internal blood supply disorders of thyroid nodules are associated with thyroid cancer. In our study, a total of 304 patients in the modeling group showed an abnormal track of blood vessels or penetration from capsule; this was found irrelevant to CNM using a single-factor analysis (\( P = 0.737 \)) (Fig. 4). These data suggest that the internal tumor blood supply may be important only in PTC, but may not be associated with the lymphatic system metastasis.

Pulse Doppler of normal thyroid arteries presented unidirectional pulsatile spectrum, having a rapid increase in systolic blood pressure that gradually fell to a low-amplitude blood flow in diastolic blood pressure. The RI was typically 0.55–0.66, and increased RI values were commonly seen in PTC and a small amount of nodular goiter cases. The main reason for this was oppression of small blood vessels by hard tumor texture or swollen follicles and hypertrophic fibrous tissue. In this study, RI > 0.7 was set as the threshold, and 622 cases had RI > 0.7, accounting for 21.7% of the total cases. Among them, 424 cases were from the modeling group. The multivariable logistic regression analysis showed that RI could be used as an independent risk factor for CNM (OR, 1.388; 95% CI, 1.092–1.763). However, other studies that evaluated the imaging of nodular hardness\textsuperscript{21,28} did not confirm its relationship with CNM, suggesting that other mechanisms might be contributing to the elevated RI values.

The tumor size has been used as a criterion for assessing PTC treatment programs and surgical ranges; larger tumor diameters are associated with cervical lymph node metastases and can increase T staging\textsuperscript{30,34}. Several retrospective analyses with large sample sizes showed that tumor size > 1 cm had higher CNM rates\textsuperscript{30–34}. An accurate measurement of the tumor size before surgery may help provide a guidance for the diagnosis. In this study, the tumor size was divided into the following four groups: \( \leq 1 \) cm, 1–2 cm, 2–3 cm, and > 3 cm. Single-factor and multivariate analyses showed that the tumor size correlated with CNM (\( P < 0.001 \)); each group could be used as an independent influencing factor and included in the predictive scoring system.

Figure 3. The same patient with postoperative pathological diagnosis of PTC and CNM (2/13). (A and B) A number of psammoma body formation on the left thyroid foci by H&E staining under 40× magnification and 100× magnification. (C and D) Visible formation of psammoma bodies inside the nodule by H&E staining under 40× and 100× magnification. H&E, hematoxylin and eosin.
Extrathyroid extension is one of the unfavorable prognostic factors for PTC. Several studies have shown that microscopic extrathyroid extensions have a less adverse effect on the prognosis of PTC patients. Moreover, microscopic invasion found in pathological slices may not provide support for timely surgical modification of individual surgical procedures. Therefore, we used intraoperative extrathyroid extension observed by naked eyes as a predictor of one of the variables in the scoring system.

Because PTC often has gland metastases at an early stage, multifocality is one of its significant features. Previous studies have suggested that multifocality could be used as an independent predictor of CNM. However, in the specimens with thyroid resection due to benign diseases, 7.3–33.9% of the cases had small foci, suggesting that using multifocality may lead to selective bias due to relaxed inclusion criteria. Improvements in US equipment and diagnostic techniques increase the detection rates of thyroid nodules. Liu et al. have suggested that the CLNM was related to multiple regions occupied by tumors in the thyroid but unrelated to multifocality.

Presently, in major hospitals of China, all thyroid nodules of >0.1 cm can be successfully found. This study was strictly based on preoperative US to determine whether multinodular lesions and all nodules (benign and malignant) were included in the analysis, to reduce interventions by human factors as much as possible. The multivariable analysis showed that it could be used as a predictor of CNM and incorporated into the scoring system.

Conventional use of US for CNM diagnosis has a high specificity, but because of low sensitivity and false negative rates, it cannot be used for diagnosis. In this study, the AUC of ROC in the modeling group was 0.742 (95% CI, 0.720–0.764), with a diagnostic sensitivity and specificity of 64.3% and 71.7%, respectively. Validation population results showed that the AUC of ROC was 0.758 (95% CI, 0.727–0.789), with a diagnostic sensitivity and specificity of 67.2% and 72.1%, respectively. In this study, 265 out of 2862 cases were diagnosed with CNM or suspicious metastasis by preoperative US direct diagnosis. The specificity was 96.5%, and the sensitivity was only 16.8%. The sensitivity of this predictive model to preoperative diagnosis of CNM was 3.8 times (64.3% vs. 16.8%) and 4 times (67.2% vs. 16.8%) of direct ultrasound diagnosis.

The CNM detection rate of the scoring system established by preoperative factors was 64.6% and 62.3%, respectively, in the modeling and validation groups of high-risk population. Although the AUC of ROC in the scoring system was 0.742 and 0.758, it was not possible to provide a higher diagnostic specificity. However, in cancer, the sensitivity in metastatic diagnosis is more important than specificity, and a timely diagnosis of patients with CNM is important for the improvement of PTC prognosis.

The predictive indicators included in this study were clinical and US results, and they were easily accessible in the preoperative stage. The US diagnostic indicators were quantified, greatly reducing the interference due to the lack of experience of the US-analyzing physicians and other clinicians. The variables required for the scoring system are the patient’s basic clinical characteristics and routine examination features (US); no invasive operations are needed. The increased sensitivity of preoperative diagnosis can help patients better understand their risk of CNM. Further research in this direction should improve the predictive value of the scoring system.

Although this study was a single-center retrospective study with a large sample size, the diagnosis and treatment processes were standardized and unified. However, some information still could not be accurately collected due to the non-standardized US reports, and human factors could not be completely eliminated. Prospective and multicenter studies are needed to confirm the accuracy of this diagnostic method and improve the scoring system. We also hope that preoperative gene detection and thyroglobulin tests will be supplemented to the scoring system in future research and other scholars’ studies would further improve sensitivity and specificity. Despite the aforementioned shortcomings, this scoring system, as a predictive model for the effective risk stratification of PTC patients using preoperative data, is simple and reliable in a clinical setting, and can be used to improve the diagnostic sensitivity as well as help clinicians in the diagnosis and treatment of PTC.

Figure 4. The left thyroid nodular showed increased nodular blood flow signals and blood supply rich and penetration from capsule by Doppler ultrasonography in the same patient.
Materials and Methods

Research design. Clinical data of patients with PTC, who were hospitalized from January 2007 to June 2016 in the Thyroid Center, the First Affiliated Hospital of Kunming Medical University, were retrospectively analyzed. After reviewing the tumor US reports and images twice, the relationship between clinical and US characteristics and CNM was analyzed to establish a predictive model and scoring system, which were then validated using validation group. The predictive diagnostic effectiveness of the scoring system was evaluated using consistency, discrimination ability, and accuracy. This study was approved by the ethics committee of the First Affiliated Hospital of Kunming Medical University (2016 Ethical Review I No. 40), and no informed consent was required.

Research subjects. The patients with PTC enrolled in the Thyroid Center of the First Affiliated Hospital of Kunming Medical University from January 2007 to June 2016 were included in the study. Their PTC conditions were confirmed by postoperative pathology. The inclusion criteria were as follows: initial thyroidectomy, postoperative paraffin pathological diagnosis of PTC, and surgical range including total central lymph node dissection (CND). The US reports were issued by more than two US physicians, and the saved images showed clear signs of major lesions. The exclusion criteria included missing information of medical record, US or thyroid function test, history of head/neck surgery or radiology, history of other malignancy, and presence of other types of thyroid cancer. Moreover, ultrasonic characteristics with the following three situations were not included in the study: (1) interference with other diseases, such as Hashimoto's disease, could not be excluded because images of US tumor echo in some tumors and surrounding muscle tissues could not be saved at the same time; (2) the composition of tumor and the peripheral blood supply in some US reports were not standardized; and (3) the length/width ratio could not be confirmed by three dimensions in the review of US images. Surgeries were performed by specialists who perform more than 100 surgeries annually. The CND range was according to the cervical lymph node division revised by the American Society of Head and Neck Surgery (2002) and American Multidisciplinary Consensus (2009). In our department, the scope of operation includes prophylactic/cure central lymph node (level VI) dissection in preoperative suspicious/diagnosis and confirmed by intraoperative frozen of all PTC patients. The upper, lower, and external bounds of CND were lower edge of hyoid bone, sternal fossa, and medial carotid artery sheath, respectively. The posterior border was anterior fascia, including all lymph nodes and adipose tissues, paratrachea, pretrachea, and prelarynx.

Data collection Methods. Age, gender, and other basic information of patients were collected through medical records. US characteristics were collected after reviewing the US reports twice along with the US images. Lesion characteristics of the most important lesions were recorded for multifocal cancer. The size of the maximum cancer nodule was selected in the multifocal carcinomas, and the longest diameter was included in the irregular shape of the carcinoma(s). Two or more nodules found by US were regarded as multiple nodular lesions, including all benign and malignant nodules, except glial nodules. Microcalcification was defined as less than 0.1 cm calcification without acoustic shadow or comet tail sign. Moreover, nodules having coarse calcification and microcalcification simultaneously were also classified as microcalcification. According to the distribution trend of microcalcification lesions in tumors, scattered distribution and aggregated distribution were divided. Irregularity or lobulated growth on the edge of tumors was defined as irregular shape. Internal blood supply was divided into rich and not rich based on the number of blood vessels in tumors using Doppler ultrasonography. Internal blood vessels with tortuous and disordered track and penetrating branches were defined as abnormal track. The blood flow resistance index (RI) of tumor was recorded as the highest measured value of all internal blood vessels. The diagnosis of Hashimoto's disease was confirmed by US as well as by using serum thyroid peroxidase antibodies. All information of US and thyroid function was collected before the last test results (within 1 month before surgery). Extrathyroid extensions included tumors that broken through the capsule, invaded the band muscle, subcutaneous tissues, nerves, or other organs.

Statistical analysis. Statistical analysis was performed using the SPSS 22.0 statistical software package (IBM, NY, USA). Two-thirds of the cases were randomly assigned into the modeling group and one-third into the validation group. Mean ± standard deviation was used for quantitative data with normal distribution. Skewed distribution used quartile and qualitative data that were expressed as rate and composition ratio. \( \chi^2 \) test was used for the hypothetical testing data in the modeling group, and variables with \( P < 0.1 \) and without significant correlation were selected for a multivariable analysis. After applying logistic regression analysis model, a backward stepwise regression was performed. Subsequent variables with \( P < 0.05 \) were selected, and variables with \( P > 0.1 \) were excluded according to the results of partial likelihood ratio test. Finally, regression equation and regression coefficients of independent variables were obtained. The selected variables in the logistic regression model were divided by minimum regression coefficient to get a score for each variable in an integer, thereby establishing the predictive scoring system of CNM in PTC. The consistency of risk assessment was assessed using Hosmer–Lemeshow goodness-of-fit test, in which \( P > 0.05 \) was considered as a good model consistency. The receiver operating characteristic (ROC) curve was used to evaluate discrimination ability of the prediction model and its scoring system. An appropriate cutoff value was selected to calculate the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) of the model. A logistic regression analysis in the validation population group was performed using the Enter method to evaluate the diagnostic efficiency of the predictive model (as mentioned earlier) and verify its clinical diagnostic value.
References

1. Lim, H., Devesa, S. S., Sosa, J. A., Check, D. & Kitahara, C. M. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974–2013. JAMA 317, 1338–1348 (2017).
2. Chen, W. et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res 29, 1–10 (2017).
3. WHO/IARC. World Cancer Report 2014. IARC Press: Lyon, 2014.
4. Cho, B. Y. et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid 23, 797–804 (2013).
5. Colonna, M. et al. Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer Epidemiol 39, 511–518 (2015).
6. Haugen, B. R. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid: Official Journal of the American Thyroid Association 123, 1 (2017).
7. Mitchell, A. L., Gandhi, A., Scott-Coombes, D. & Perros, P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 130, S150–S160 (2016).
8. Teng, W., Liu, Y. & Gao, M. Management guidelines for thyroid nodules and differentiated thyroid cancer. Chin J Endocrinol Metab 28, 779–797 (2012).
9. Luo, B. & Zhao, Y. Role of ultrasonography in the preoperative differential diagnosis of thyroid nodules: an ultrasonographic-pathologic analysis for 2890 patients with 4165 nodules. Chin J End Met 26, 282–284 (2010).
10. American Thyroid Association Surgery Working, G. et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 19, 1153–1158 (2009).
11. Noh, T. A. et al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg 34, 1187–1191 (2010).
12. Yan, H. et al. A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients. Int J Endocrinol 2016, 1878194 (2016).
13. Hwang, H. S. & Orloff, L. A. Efficacy of prophylactic neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. Laryngoscope 121, 487–491 (2011).
14. Lee, D. W. et al. Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. Eur J Surg Oncol 39, 191–196 (2013).
15. Khokhar, M. T. et al. Preoperative High-Resolution Ultrasound for the Assessment of Malignant Central Compartment Lymph Nodes in Papillary Thyroid Cancer. Thyroid 25, 1351–1354 (2015).
16. Lee, Y. J. et al. Pre-operative ultrasound diagnosis of nodal metastasis in papillary thyroid carcinoma patients according to nodal compartment. Ultrasound Med Biol 41, 1294–1300 (2015).
17. Zhang, L. et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab 97, 1250–1257 (2012).
18. Nam, I. C., Park, J. O., Joo, Y. H., Cho, K. J. & Kim, M. S. Pattern and predictive factors of regional lymph node metastasis in papillary thyroid carcinoma: a prospective study. Head Neck 35, 40–45 (2013).
19. Malandrinos, P. et al. Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab 98, 1427–1434 (2013).
20. Xiang, D. et al. Papillary thyroid microcarcinomas located at the middle part of the middle third of the thyroid gland correlates with the presence of neck metastasis. Surgery 157, 526–533 (2015).
21. Hong, Y. R. et al. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. J Clin Ultrasound 43, 1089–1099 (2015).
22. Ma, J. J. et al. Diagnostic performances of various gray-scale, color Doppler, and contrast-enhanced ultrasonography findings in predicting malignant thyroid nodules. Thyroid 24, 355–363 (2014).
23. Lai, X. J. et al. High Risk of Lateral Nodal Metastasis in Lateral Solitary Solid Papillary Thyroid Cancer. Ultrasound Med Biol 42, 75–81 (2016).
24. Kwak, J. Y. et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology 260, 892–899 (2011).
25. Brito, J. P. et al. The accuracy of thyroid nodule imaging to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab 99, 2003–2025 (2014).
26. Moon, H., Kwak, Y. J., Kim, M. J., Son, E. J. & Kim, E. K. Can vascularity at power Doppler US help predict thyroid malignancy? Radiology 235, 260–269 (2010).
27. Adamczyk, Z. & Lewinski, A. Proposed algorithm for management of patients with thyroid nodules/focal lesions, based on thyroid ultrasound (US) and fine-needle aspiration biopsy (FNAB): our own experience. Thyroid Res 9, 7748 (2015).
28. Ma, J. J. et al. Clinical implication of elastography as a prognostic factor of papillary thyroid microcarcinoma. Ann Surg Oncol 19, 2279–2287 (2012).
29. Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67, 93–99 (2017).
30. Ito, Y. et al. Tumor size is the strongest predictor of microscopic lymph node metastasis and lymph node recurrence of N0 papillary thyroid carcinoma. Endocr 60, 113–117 (2013).
31. Liang, K., He, L., Dong, W. & Zhang, H. Risk factors of central lymph node metastasis in cN0 papillary thyroid carcinoma: a study of 529 patients. Med Sci Monit 20, 807–813 (2014).
32. Jiang, L. H. et al. Clinical Characteristics Related to Central Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma: A Retrospective Study of 916 Patients. Int J Endocrinol 2014, 385787 (2014).
33. Lang, B. H. et al. Is BRAFV600E mutation a marker for central nodal metastasis in small papillary thyroid carcinoma? Endocr Relat Cancer 21, 285–295 (2014).
34. Xue, S. et al. Prophylactic central lymph node dissection in cN0 patients with papillary thyroid carcinoma: A retrospective study in China. Asian J Surg 39, 131–136 (2016).
35. Riemann, B. et al. Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trial. Nuklearmedizin 49, 79–84 (2010).
36. Nixon, I. J. et al. The impact of microscopic extrathyroidal extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery 150, 1242–1249 (2011).
37. Radowsky, J. S., Howard, R. S., Burch, H. B. & Stojadinovic, A. Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. Thyroid 24, 241–244 (2014).
38. Zhang, L. Y., Liu, Z. W., Liu, Y. W., Gao, W. S. & Zheng, C. J. Risk Factors for Nodal Metastasis in cN0 Papillary Thyroid Microcarcinoma. Asian Pac J Cancer Prev 16, 3361–3363 (2015).
39. Liu, Z., Wang, L., Yi, P., Wang, C. Y. & Huang, T. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a meta-analysis. Int J Clin Exp Pathol 7, 932–937 (2014).
40. Chen, A. Y., Jermal, A. & Ward, E. M. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 115, 3801–3807 (2009).
41. Colonna, M. *et al.* A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000). *Eur J Cancer* **43**, 891–900 (2007).
42. Cramer, J. D., Fu, P., Harth, K. C., Margevicius, S. & Wilhelm, S. M. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. *Surgery* **148**, 1147–1152; discussion 1152–1143 (2010).
43. de Matos, P. S., Ferreira, A. P. & Ward, L. S. Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series. *Endocr Pathol* **17**, 165–173 (2006).
44. Elisei, R. *et al.* Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. *J Clin Endocrinol Metab* **95**, 1516–1527 (2010).
45. Rego-Iraeta, A., Perez-Mendez, L. F., Mantinan, B. & Garcia-Mayor, R. V. Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. *Thyroid* **19**, 333–340 (2009).
46. Sakorafas, G. H. *et al.* Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably benign thyroid disease. *J Postgrad Med* **53**, 23–26 (2007).
47. Liu, W. *et al.* Risk factors of central lymph node metastasis of papillary thyroid carcinoma: A single-center retrospective analysis of 3273 cases. *Medicine (Baltimore)* **96**, e8365 (2017).
48. Kandil, E., Noureldine, S. I., Abbas, A. & Tufano, R. P. The impact of surgical volume on patient outcomes following thyroid surgery. *Surgery* **154**, 1346–1352; discussion 1352–1343 (2013).
49. American Thyroid Association Guidelines Taskforce on Thyroid, N. *et al.* Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* **19**, 1167–1214 (2009).
50. Gregory, W. Randolph. *Surgery of thyroid and parathyroid glands*. Elsevier: Singapore, 2013.
51. Hosmer, D. & Lemeshow, S. *Applied logistic regression*, 2nd edn. John Willey & Sons: New York, 2000.

**Author Contributions**

W.L. conceived and designed the study, carried out the data collection, performed and analyzed the experiments, and wrote the paper. R.C. was responsible for the study coordination and direction. Y.M. and D.W. directed reading ultrasonic images and collecting ultrasound characteristics. Y.S., C.D., J.Z., J.Q. and J.L. participated in the operation and management. All authors reviewed the results and approved the final version of the manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018